Evidence map›Paper›PMID 42215940›Full record

ArticleBMC cancer2026

Safety, pharmacokinetics, pharmacodynamics and antitumor activity of legubicin in patients with advanced solid tumors, including lung cancer: a phase 1 dose-escalation and expansion trial.

Fengjuan Lin, Junli Xue, Qun Li, Wenbo Tang, Wei Zhao, Liqiong Xue, Jiuli Zhou, Yuan Liu, Wenyue Jin, Hui Sun and 3 more

Abstract readClinical Trial, Phase IMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Fengjuan Lin *Department of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, 1800 Yuntai Road, Shanghai, 200123, China.
Junli Xue *Department of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, 1800 Yuntai Road, Shanghai, 200123, China.
Qun LiDepartment of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, 1800 Yuntai Road, Shanghai, 200123, China.
Wenbo TangDepartment of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, 1800 Yuntai Road, Shanghai, 200123, China.
Wei ZhaoDepartment of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, 1800 Yuntai Road, Shanghai, 200123, China.
Liqiong XueDepartment of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, 1800 Yuntai Road, Shanghai, 200123, China.
Jiuli ZhouDepartment of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, 1800 Yuntai Road, Shanghai, 200123, China.
Yuan LiuResearch & Development Department, Affinity (Shanghai) Biopharmaceutical Co., Ltd, 368 Zhangjiang Road, Shanghai, 201210, China.
Wenyue JinClinical Development Department, Affinity (Shanghai) Biopharmaceutical Co., Ltd, 368 Zhangjiang Road, Shanghai, 201210, China.
Hui SunClinical Development Department, Affinity (Shanghai) Biopharmaceutical Co., Ltd, 368 Zhangjiang Road, Shanghai, 201210, China.
Cheng LiuManagement and Clinical Operations, Affinity (Shanghai) Biopharmaceutical Co., Ltd., 368 Zhangjiang Road, Shanghai, 201210, China. chengliu@affinity.net.cn.
Ye GuoDepartment of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, 1800 Yuntai Road, Shanghai, 200123, China. pattrickguo@gmail.com.
Jin LiDepartment of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, 1800 Yuntai Road, Shanghai, 200123, China. lijin@csco.org.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis first-in-human, phase 1a/b dose escalation and expansion trial investigated the safety and antitumor activities of legubicin, a novel conjugate of doxorubicin with a legumain-cleavable tetrapeptide linker, for patients with advanced solid tumors who failed or had no applicable standard of care treatment.

methodsEligible patients received legubicin over 7 dose levels from 20 mg/m

resultsPhase 1a enrolled 28 patients (median age 57.5 years; men 60.7% [17/28]) and phase 1b enrolled 35 (median age 53.0 years, men 51.4% [18/35]), with 15 in the 270 mg/m

conclusionsLegubicin is safe and well tolerated at a dose of 270 mg/m

trial registrationChinese Clinical Trial Registry ( http://www.chictr.org.cn/ , ChiCTR2600122142; registered on April 9, 2026).

Indexed as

Antineoplastic AgentsDoxorubicinLung NeoplasmsNeoplasmsAdultAgedDose-Response Relationship, DrugFemaleHumansMaleMaximum Tolerated DoseMiddle AgedAntineoplastic AgentsDoxorubicinAntitumor activitiesDoxorubicinLegubicinLegumainPhase 1a/b trialSafetySolid tumorsTolerabilities

Identifiers

PMID42215940
PMCPMC13436135

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.